JP2019532919A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532919A5 JP2019532919A5 JP2019512640A JP2019512640A JP2019532919A5 JP 2019532919 A5 JP2019532919 A5 JP 2019532919A5 JP 2019512640 A JP2019512640 A JP 2019512640A JP 2019512640 A JP2019512640 A JP 2019512640A JP 2019532919 A5 JP2019532919 A5 JP 2019532919A5
- Authority
- JP
- Japan
- Prior art keywords
- theta
- compound
- pharmaceutically acceptable
- acceptable salt
- crystalline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000634 powder X-ray diffraction Methods 0.000 claims 49
- 150000003839 salts Chemical class 0.000 claims 45
- 229940125782 compound 2 Drugs 0.000 claims 31
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims 24
- 229940125904 compound 1 Drugs 0.000 claims 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 8
- 238000004458 analytical method Methods 0.000 claims 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Chemical class OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical class [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical class [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 150000008064 anhydrides Chemical class 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical class OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical class O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical class [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Chemical class 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 150000003890 succinate salts Chemical group 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- -1 which are methylate Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662384596P | 2016-09-07 | 2016-09-07 | |
| US62/384,596 | 2016-09-07 | ||
| PCT/US2017/050332 WO2018048943A1 (en) | 2016-09-07 | 2017-09-06 | Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019532919A JP2019532919A (ja) | 2019-11-14 |
| JP2019532919A5 true JP2019532919A5 (enExample) | 2020-10-15 |
| JP7079772B2 JP7079772B2 (ja) | 2022-06-02 |
Family
ID=61561660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019512640A Active JP7079772B2 (ja) | 2016-09-07 | 2017-09-06 | リシルオキシダーゼ様2阻害剤の結晶形態および製造方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10774069B2 (enExample) |
| EP (1) | EP3510023B1 (enExample) |
| JP (1) | JP7079772B2 (enExample) |
| KR (1) | KR102587178B1 (enExample) |
| CN (1) | CN109983006B (enExample) |
| AU (1) | AU2017324445A1 (enExample) |
| BR (1) | BR112019004517A2 (enExample) |
| CA (1) | CA3036064A1 (enExample) |
| EA (1) | EA201990621A1 (enExample) |
| IL (1) | IL265192A (enExample) |
| MA (1) | MA46204A (enExample) |
| MX (1) | MX390964B (enExample) |
| SG (1) | SG11201901999XA (enExample) |
| WO (1) | WO2018048943A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3795568A1 (en) | 2015-03-06 | 2021-03-24 | Pharmakea, Inc. | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof |
| JP6800872B2 (ja) * | 2015-03-06 | 2020-12-16 | ファーマケア,インク. | リシルオキシダーゼ様2阻害剤とその使用 |
| CA3013917A1 (en) | 2016-02-09 | 2017-08-17 | Pharmakea, Inc. | Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof |
| JP7097874B2 (ja) | 2016-09-07 | 2022-07-08 | ファーマケア,インク. | リシルオキシダーゼ様2阻害剤の使用 |
| AU2017324445A1 (en) | 2016-09-07 | 2019-04-11 | Pharmakea, Inc. | Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making |
| GB201716871D0 (en) | 2017-10-13 | 2017-11-29 | Inst Of Cancer Research: Royal Cancer Hospital | Compounds |
| CN114487139B (zh) * | 2020-10-27 | 2025-01-14 | 鲁南制药集团股份有限公司 | 一种盐酸西替利嗪有关物质的检测方法 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
| IE56702B1 (en) | 1982-12-01 | 1991-11-06 | Usv Pharma Corp | Antiinflammatory antiallergic compounds |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| US5021456A (en) | 1988-02-25 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
| US5563143A (en) | 1994-09-21 | 1996-10-08 | Pfizer Inc. | Catechol diether compounds as inhibitors of TNF release |
| US6956047B1 (en) | 1995-06-06 | 2005-10-18 | Pfizer Inc. | Corticotropin releasing factor antagonists |
| US7067664B1 (en) | 1995-06-06 | 2006-06-27 | Pfizer Inc. | Corticotropin releasing factor antagonists |
| US6632823B1 (en) | 1997-12-22 | 2003-10-14 | Merck & Co., Inc. | Substituted pyridine compounds useful as modulators of acetylcholine receptors |
| HRP20020599A2 (en) | 2000-01-18 | 2004-08-31 | Pfizer Prod Inc | Corticotropin releasing factor antagonists |
| US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US20030134836A1 (en) | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
| US20020147198A1 (en) | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
| US7307088B2 (en) | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
| FI20030030A0 (fi) | 2003-01-09 | 2003-01-09 | Orion Corp | Uusia yhdisteitä |
| ATE537825T1 (de) | 2003-05-19 | 2012-01-15 | Irm Llc | Immunosuppressive verbindungen und zusammensetzungen |
| BRPI0507250A (pt) | 2004-01-29 | 2007-06-26 | Pfizer Prod Inc | combinações para tratar desordens do snc |
| US7381750B2 (en) | 2004-03-12 | 2008-06-03 | Eli Lilly And Company | Amino-phenoxymethyl-benzamide opioid receptor antagonists |
| ATE545413T1 (de) | 2004-03-15 | 2012-03-15 | Lilly Co Eli | Antagonisten des opioidrezeptors |
| CA2564085C (en) | 2004-04-30 | 2013-04-02 | Takeda Pharmaceutical Company Limited | Heterocyclic amide compound and use thereof as an mmp-13 inhibitor |
| US7507748B2 (en) | 2004-07-22 | 2009-03-24 | Amgen Inc. | Substituted aryl-amine derivatives and methods of use |
| WO2006027691A2 (en) | 2004-09-10 | 2006-03-16 | Pfizer Products Inc. | Methods of treating mood disorders using benzisoxazole containing diazabicyclic compounds |
| MX2007002842A (es) | 2004-09-10 | 2007-04-30 | Pfizer Prod Inc | Metodos de tratamiento de trastornos cognitivos que usan derivados azabiciclicos de piridiloximetilo y benzoisoxazol. |
| WO2006052546A2 (en) | 2004-11-04 | 2006-05-18 | Neurogen Corporation | Pyrazolylmethyl heteroaryl derivatives |
| DE102004056226A1 (de) | 2004-11-22 | 2006-05-24 | Burchardt, Elmar Reinhold, Dr.Dr. | Neuartige Inhibitoren der Lysyloxidase |
| AU2006210954A1 (en) | 2005-01-31 | 2006-08-10 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
| AR055041A1 (es) | 2005-03-23 | 2007-08-01 | Merck Frosst Canada Ltd | Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas. |
| AU2006279211A1 (en) | 2005-08-11 | 2007-02-15 | Merck Frosst Canada Ltd | Novel substituted 1,2,3-triazolylmethyl-benzothiophene or -indole and their use as leukotriene biosynthesis inhibitors |
| US7405302B2 (en) | 2005-10-11 | 2008-07-29 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| ITMI20051943A1 (it) * | 2005-10-14 | 2007-04-15 | Procos Spa | Processo di risoluzione anantiomerica di 2-aminometil-pirrolidine 1-sostitute per ammidazione in presenza di lipasi |
| US20070225285A1 (en) | 2005-11-04 | 2007-09-27 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| US20070219206A1 (en) | 2005-11-04 | 2007-09-20 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| CA2636043A1 (en) | 2006-01-23 | 2007-08-02 | Amira Pharmaceuticals, Inc. | Tricyclic inhibitors of 5-lipoxygenase |
| GB0614579D0 (en) | 2006-07-21 | 2006-08-30 | Black James Foundation | Pyrimidine derivatives |
| WO2008020799A1 (en) | 2006-08-18 | 2008-02-21 | Astrazeneca Ab | Thienopyrimidin-4-one and thienopyridazin-7-one derivatives as mch rl antagonists |
| IL184627A0 (en) | 2007-07-15 | 2008-12-29 | Technion Res & Dev Foundation | Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue |
| CN110372795A (zh) | 2007-08-02 | 2019-10-25 | 吉利德生物制剂公司 | Lox和loxl2抑制剂及其应用 |
| JP2013500974A (ja) | 2009-07-28 | 2013-01-10 | アナコール ファーマシューティカルズ,インコーポレイテッド | 三置換ホウ素含有分子 |
| AU2010284001A1 (en) | 2009-08-21 | 2012-03-22 | Gilead Biologics, Inc. | Therapeutic methods and compositions |
| RU2015108348A (ru) | 2010-02-04 | 2015-07-20 | Джилид Байолоджикс, Инк. | Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения |
| CN103002742B (zh) | 2010-03-05 | 2016-07-13 | 卡尔约药物治疗公司 | 核转运调节剂及其应用 |
| CN103415515B (zh) | 2010-11-19 | 2015-08-26 | 因塞特公司 | 作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物 |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
| WO2013059587A1 (en) | 2011-10-20 | 2013-04-25 | Sirtris Pharmaceuticals, Inc. | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
| US9701658B2 (en) | 2012-04-25 | 2017-07-11 | Raqualia Pharma Inc. | Amide derivatives as TTX-S blockers |
| SG11201503065PA (en) | 2012-10-30 | 2015-05-28 | Gilead Sciences Inc | Therapeutic and diagnostic methods related to lysyl oxidase-like 2 (loxl2) |
| WO2014098098A1 (ja) | 2012-12-18 | 2014-06-26 | 味の素株式会社 | 複素環アミド誘導体及びそれを含有する医薬 |
| CA2939655A1 (en) | 2014-02-14 | 2016-02-11 | The University Of British Columbia | Modulators of caspase-6 |
| US9051320B1 (en) | 2014-08-18 | 2015-06-09 | Pharmakea, Inc. | Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor |
| CN107922392B (zh) | 2015-02-15 | 2020-07-21 | 豪夫迈·罗氏有限公司 | 1-(杂)芳基磺酰基-(吡咯烷或哌啶)-2-甲酰胺衍生物及其用途 |
| JP6800872B2 (ja) | 2015-03-06 | 2020-12-16 | ファーマケア,インク. | リシルオキシダーゼ様2阻害剤とその使用 |
| EP3795568A1 (en) * | 2015-03-06 | 2021-03-24 | Pharmakea, Inc. | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof |
| JP7097874B2 (ja) | 2016-09-07 | 2022-07-08 | ファーマケア,インク. | リシルオキシダーゼ様2阻害剤の使用 |
| AU2017324445A1 (en) * | 2016-09-07 | 2019-04-11 | Pharmakea, Inc. | Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making |
-
2017
- 2017-09-06 AU AU2017324445A patent/AU2017324445A1/en not_active Abandoned
- 2017-09-06 EA EA201990621A patent/EA201990621A1/ru unknown
- 2017-09-06 CA CA3036064A patent/CA3036064A1/en active Pending
- 2017-09-06 SG SG11201901999XA patent/SG11201901999XA/en unknown
- 2017-09-06 JP JP2019512640A patent/JP7079772B2/ja active Active
- 2017-09-06 US US16/331,095 patent/US10774069B2/en active Active
- 2017-09-06 MX MX2019002615A patent/MX390964B/es unknown
- 2017-09-06 WO PCT/US2017/050332 patent/WO2018048943A1/en not_active Ceased
- 2017-09-06 BR BR112019004517-1A patent/BR112019004517A2/pt not_active IP Right Cessation
- 2017-09-06 CN CN201780068733.0A patent/CN109983006B/zh active Active
- 2017-09-06 MA MA046204A patent/MA46204A/fr unknown
- 2017-09-06 KR KR1020197009870A patent/KR102587178B1/ko active Active
- 2017-09-06 EP EP17849479.5A patent/EP3510023B1/en active Active
-
2019
- 2019-03-06 IL IL265192A patent/IL265192A/en unknown
-
2020
- 2020-08-03 US US16/983,759 patent/US11459309B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019532919A5 (enExample) | ||
| JP2010539237A5 (enExample) | ||
| JP2013523733A5 (enExample) | ||
| JP2014515013A5 (enExample) | ||
| JP2009502795A5 (enExample) | ||
| JP2019514863A5 (enExample) | ||
| JP2012507535A5 (enExample) | ||
| CA2553887C (en) | Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | |
| JP2010516681A5 (enExample) | ||
| JP2018509458A5 (enExample) | ||
| JP2015518885A5 (enExample) | ||
| JP2017520613A5 (enExample) | ||
| JP2010505906A5 (enExample) | ||
| JP2012509263A5 (enExample) | ||
| JP2016000739A5 (enExample) | ||
| JP2015531774A5 (enExample) | ||
| US9376419B2 (en) | Solid forms of nilotinib hydrochloride | |
| JP2016503010A5 (enExample) | ||
| JP2012526766A5 (enExample) | ||
| RU2019112080A (ru) | Соли производного индазола и их кристаллы | |
| JP2017509611A5 (enExample) | ||
| JP2015506987A5 (enExample) | ||
| JP2013541589A5 (enExample) | ||
| JP2011500575A5 (enExample) | ||
| WO2016024289A2 (en) | Novel salts of nilotinib and polymorphs thereof |